Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
Affinivax IncDeal completed31 May 202231 May 2022Deal completed-33.44%3.30bn
Sierra Oncology IncDeal completed13 Apr 202213 Apr 2022Deal completed-35.52%2.08bn
Data delayed at least 20 minutes, as of Mar 23 2023 17:40 BST.

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
Quaestio Capital Management SGR SpAas of 30 Jun 2022474.08k0.00%
Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 2022380.36k0.00%
Niche Asset Management Ltd.as of 30 Jun 2022177.60k0.00%
FWU Life Insurance Austria AGas of 30 Jun 202299.17k0.00%
Geode Capital Management LLCas of 30 Nov 202257.10k0.00%
Altrinsic Global Advisors LLCas of 30 Jun 202253.94k0.00%
Professionals� Financial � Mutual Funds Inc.as of 30 Jun 202246.61k0.00%
Fuh Hwa Securities Investment Trust Co., Ltd.as of 16 Mar 202343.71k0.00%
Counsel Portfolio Services, Inc.as of 30 Sep 202231.24k0.00%
Select INVESTMENT GmbHas of 30 Jun 202221.23k0.00%
More ▼
Data from 30 Jun 2022 - 16 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.